Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pashna N. Munshi"'
Autor:
Reem Karmali, Ayman Saad, Kwang Woo Ahn, Melhem Solh, Ravi Vij, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Timothy S. Fenske, William A. Wood, Mehdi Hamadani, Amir Steinberg, Carlos Litovich, Pashna N. Munshi, Alexsandr Lazaryan, Usama Gergis, Siddhartha Ganguly, David J. Inwards, Sonali M. Smith, Lazaros J. Lekakis, Anna Sureda, Farrukh T. Awan, Sunita Nathan
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-10 (2019)
Blood Cancer Journal
Blood Cancer Journal
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for relapsed/refractory and high-risk non-Hodgkin lymphoma (NHL). However, no large studies have evaluated allo-HCT utilization in elderly NHL patients (≥65 years). Usin
Autor:
Chaitra S. Ujjani, Pashna N. Munshi
Publikováno v:
Hematological oncologyREFERENCES. 37(3)
Recent advances in diffuse large B-cell lymphomas have included both identification of high-risk subtypes characterized by multiply relapsed and/or refractory disease as well as novel treatment in the form of cellular therapy. Chimeric antigen recept
Autor:
Julio C. Chavez, Ibrahim Yakoub-Agha, Carla Casulo, Sattva S. Neelapu, Lori A. Leslie, Sven de Vos, Mauro P. Avanzi, Yin Yang, Javier Munoz, Caron A. Jacobson, Henry C. Fung, David G. Maloney, Pashna N. Munshi, Basem M. William, Alison R. Sehgal, Vicki Plaks, Ran Reshef, Olalekan O. Oluwole, Gilles Salles, Jennifer Lee
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S278
Objective: Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL. Design: Adults with relapsed/refractory follicular
Autor:
David H. Vesole, Tatyana Feldman, Andre Goy, Noa Biran, Lori A. Leslie, Scott D. Rowley, Michele L. Donato, Michael B. Atkins, Andrew L. Pecora, David S. Siegel, Alan P Skarbnik, Robert Korngold, Rena Feinman, Pashna N. Munshi
Publikováno v:
Blood. 132:256-256
Rationale: ASCT remains a standard-of-care as consolidation or salvage for multiple myeloma (MM), post-salvage consolidation for Diffuse Large B-Cell Lymphoma (DLBCL) and upfront consolidation or salvage for Peripheral T-Cell Lymphomas (PTCL) Pts wit
Autor:
Stacey L. Fanning, Kira Goldgirsh, Michael B. Atkins, David S. Siegel, Robert Korngold, Michele L. Donato, Zheng Yang, Alan P Skarbnik, Andrew L. Pecora, Tatyana Feldman, Rena Feinman, Lori A. Leslie, Andre Goy, David H. Vesole, Noa Biran, Scott D. Rowley, Dante B. Descalzi-Montoya, Pashna N. Munshi
Publikováno v:
Blood. 132:3421-3421
BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is now the standard of care for newly diagnosed MM and refractory DLBCL patients. However, relapse remains the primary cause of morbidity and mortality, and th
Autor:
Stefan O. Ciurea, Shannon R. McCurdy, Trevor Argall, Rachel B. Salit, Sameh Gaballa, Omotayo Fasan, Robert J. Soiffer, Asad Bashey, John R. Wingard, Mary Eapen, Miguel-Angel Perales, Paul O'Donnell, Andrew St. Martin, Melhem Solh, Pashna N. Munshi, Mary M. Horowitz, Vanderson Rocha, Monzr M. Al Malki, Daniel J. Weisdorf, Kavita Raj, Mei-Jie Zhang, Mehdi Hamadani, Ryotaro Nakamura, Ephraim J. Fuchs, Claudio Anasetti, Scott D. Rowley, Rizwan Romee
Publikováno v:
Blood. 128:683-683
T cell-replete haploidentical donor transplants (HAPLO-HCT) using post-transplant cyclophosphamide for control of alloreactivity is now being increasingly utilized. HAPLO-HCTs were originally performed using BM grafts. However, recently, a few single